WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018019188) POLYMORPH OF NUCLEOSIDE PHOSPHORAMIDATE PRODRUG AND PREPARATION METHOD THEREFOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/019188    International Application No.:    PCT/CN2017/093925
Publication Date: 01.02.2018 International Filing Date: 21.07.2017
IPC:
C07H 19/10 (2006.01), C07H 1/06 (2006.01), A61K 31/7068 (2006.01), A61P 35/00 (2006.01)
Applicants: BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. [CN/CN]; Building C25, No. 218 Xinghu Street, Bio-BAY, Industrial Park Suzhou, Jiangsu 215123 (CN)
Inventors: YUAN, Jiandong; (CN).
GU, Jianing; (CN).
HUANG, Yangqing; (CN).
MIAO, Linfeng; (CN).
LIANG, Chaohua; (CN).
SUN, Zhanli; (CN)
Agent: LINDA LIU & PARTNERS; F16 Tower C, Beijing Global Trade Center, 36 North Third Ring East Road, Dongcheng District Beijing 100013 (CN)
Priority Data:
201610583741.6 23.07.2016 CN
Title (EN) POLYMORPH OF NUCLEOSIDE PHOSPHORAMIDATE PRODRUG AND PREPARATION METHOD THEREFOR
(FR) POLYMORPHE DE PROMÉDICAMENT DE NUCLÉOSIDE PHOSPHORAMIDATE ET SON PROCÉDÉ DE PRÉPARATION
(ZH) 核苷氨基磷酸酯类前药的多晶型及其制备方法
Abstract: front page image
(EN)Provided are a crystal form A of a nucleoside phosphoramidate prodrug as shown in formula I and a preparation method therefor. The crystal form A at least has an X-ray powder diffraction (XRPD) pattern with peaks at the 2θ angles of 6.9 ± 0.2°, 13.9 ± 0.2°, 20.8 ± 0.2° and 21.1 ± 0.2°. The crystal form A is stable in nature and suitable for being prepared into various dosage forms. The preparation method is simple in operation, and the prepared crystal form A is high in purity and low in industrialization costs.
(FR)L'invention concerne une forme cristalline A d'un promédicament de phosphoramidate de nucléoside tel que présenté dans la formule I et un procédé de préparation associé. La forme cristalline A présente au moins une diffraction des rayons X sur poudre (XRPD) avec des pics aux angles 2θ de 6.9 ± 0.2°, 13.9 ± 0.2°, 20.8 ± 0.2° et 21.1 ± 0.2°. La forme cristalline A est de nature stable et appropriée pour être préparée en diverses formes posologiques. Le procédé de préparation est simple à utiliser, et la forme cristalline préparée A est de haute pureté et présente un faible coût d'industrialisation.
(ZH)提供一种式I所示核苷氨基酸磷酸酯类前药的晶型A及其制备方法,所述晶型A在X-射线粉末衍射(XRPD)图上至少在下述2θ角有峰:6.9±0.2、13.9±0.2、20.8±0.2和21.1±0.2。所述晶型A性质稳定,适合制成各种剂型,所述制备方法操作简单,制得的晶型A纯度高,工业化成本低。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)